In conclusion, our data indicate that a potent p38 MAPK inhibitor, FR167653, blocks PTHrP-induced osteoclastogenesis in vitro, and bone resorption and hypercalcemia in vivo. The gene discussed is PTHLH; the disease is hypercalcemia disease.